Roche has secured FDA approval to launch a late-stage trial by early April to assess the efficacy of its drug Actemra, or tocilizumab, in critically ill patients with COVID-19 who are hospitalized with pneumonia. China approved use of the interleukin-6 inhibitor to treat COVID-19 patients with severe lung damage who have elevated IL-6 levels in the blood.
Roche plans trial for Actemra as COVID-19 treatment
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.